Advisers to the US Food and Drug Administration voted Friday in favor of recommending authorization for emergency use of a Pfizer booster vaccine in high-risk groups.
That is, people 65 years of age and older, and those with the probability of suffering a severe disease as a result of covid-19.
Dr. Elmer Huerta explains this decision, which still needs to complete its authorization process with the country's health authorities.